We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Epigenetic Treatment Supports Spinal Cord Regeneration in Mice
News

Epigenetic Treatment Supports Spinal Cord Regeneration in Mice

Epigenetic Treatment Supports Spinal Cord Regeneration in Mice
News

Epigenetic Treatment Supports Spinal Cord Regeneration in Mice

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Epigenetic Treatment Supports Spinal Cord Regeneration in Mice"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Currently, spinal cord injury does not have any effective treatments. Physical rehabilitation can help patients regain some mobility but, for severe cases, the outcomes are extremely limited by the failure of spinal neurons to regenerate naturally after injury.


However, new research led by Professor Simone Di Giovanni and published in the journal PLOS Biology shows that weekly treatments with an epigenetic activator can aid the regrowth of sensory and motor neurons in the spinal cord when given to mice 12 weeks after severe injury.


Researchers used a small molecule called TTK21 to activate genetic programming that induces axon (nerve fibre) regeneration in neurons. TTK21 changes the epigenetic state of genes by activating the CBP/p300 family of co-activator proteins. The team tested TTK21 treatment in a mouse model of severe spinal cord injury. The mice lived in an enriched environment that gave them opportunities to be physically active, as is encouraged in human patients.


Treatment began 12 weeks after severe spinal cord injury and lasted for 10 weeks. Researchers found several improvements after TTK21 treatment compared with control treatment. The most noticeable effect was more axon sprouting in the spinal cord. They also found that retraction of motor axons above the point of injury halted, and that sensory axon growth increased. These changes were likely due to the observed increase in gene expression related to regeneration.


While the approach remains a long way from being trialled in human patients, the researchers say their early findings are encouraging. The next step will be to further enhance these effects and trigger the regenerating axons to reconnect to the rest of the nervous system so that animals can regain their ability to move with ease.


Professor Di Giovanni commented: “This work shows that a drug called TTK21, when administered systemically once/week after a chronic spinal cord injury (SCI) in animals, can promote neuronal regrowth and an increase in synapses that are needed for neuronal transmission.


“This is important because chronic spinal cord injury is a condition without a cure where neuronal regrowth and repair fail. We are now exploring the combination of this drug with strategies that bridge the spinal cord gap such as biomaterials as possible avenues to improve disability in SCI patients.”


Reference: Müller F, Virgiliis FD, Kong G, et al. CBP/p300 activation promotes axon growth, sprouting, and synaptic plasticity in chronic experimental spinal cord injury with severe disability. PLOS Biol. 2022;20(9):e3001310. doi: 10.1371/journal.pbio.3001310


This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

 
Advertisement